The objective of this multicenter clinical trial is to determine if hydroxyurea therapy is effective in the prevention of the onset of chronic end organ damage as determined by surrogate markers in pediatric patients with sickle cell anemia. This clinical trial involves the cooperation of pediatric Clinical Sites with expertise in treating sickle cell anemia, and a coordinating center which oversees drug distribution, central laboratory functions, and data collection.
The LTRC is a study designed to collect clinical data, lung tissues, and CT scans from participants with Chronic Obstructive Pulmonary Disease or Interstitial Lung Disease. The primary goal of the study is to link clinical information, CT data files, and study tissue specimens and blood specimens so that investigators can analyze data and specimens of studies they have designed. C-TASC coordinates the collection of these materials and their distribution to LTRC or external investigators once the investigator’s study is approved by an independent Protocol Review Committee.
The Cardiac Status of HAART Exposed HIV-infected Infants is a substudy of the WITS designed to investigate the influence of anti-retroviral therapy on HIV-infected children’s cardiac systems. There are eight Clinical Sites and currently 71 children have been recruited. In addition to the WITS data that are collected, the study includes laboratory evaluations of serial echocardiograms.
This study is designed to investigate the influence of HIV and Highly Active Antiretroviral Therapies (HAART) in the development of pulmonary complications in response to the progression and treatment of HIV infections. The study will have seven research cores of investigators who will be conducting independent research. These investigators will then submit standardized data to a central coordinating center for the purpose of conducting cooperative studies to assess the impact of HIV infection and its treatment on the respiratory system of HIV-infected individuals.
Despite observations suggesting a potential benefit for late opening of infarct-related arteries (IRA) post MI, the Occluded Artery Trial (OAT) demonstrated that PCI post MI in stable patients, with an occluded IRA, did not reduce the occurrence of events over 3.2 years mean follow-up. There was a trend toward more nonfatal reinfaction in the PCI group. The objective of OAT-LTFU was to assess the long term effect of PCI vs. medical therapy alone on 1) composite of death, MI, and heart failure, and 2) rates of different types of MI classified by the universal definition.